Activating the GPR133 receptor with a small molecule can rebuild bone from within, offering a new direction for osteoporosis ...

Phin Therapeutics, a company specializing in protein degradation-based drug development, announced on November 20 that it has begun dosing the first ...

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025Cash of $48.7 million as ...

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

This important study reports the development of the first tankyrase degrader and demonstrates its enhanced ability to inhibit β-catenin signaling compared to conventional tankyrase inhibitors. The ...

The authors have performed a potentially valuable new kind of analysis in connectomics, mapping to an interesting developmental problem of synaptic input to sensory neurons. While the analysis itself ...

DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, ...